Sotera buys Reflectance for vitals monitoring tech; FDA panel recommends Avedro's drug-device combo;

@FierceMedDev: Reuters: Boston Scientific close to $2B deal for Endo's AMS device unit. Report | Follow @FierceMedDev

@VarunSaxena2: From my med tech M&A special report: Zimmer swallowing up Biomet, leading to chain of other deals. More | Follow @VarunSaxena2

@EmilyWFierce: Get this week's ed. of FierceDiagnostics here, feat. 23andMe, $RHHBY and a new collaboration for Alzheimer's Dx. Newsletter | Follow @EmilyWFierce

> The FDA has classified powered exoskeletons as class II medical devices, which require special controls in order to assure safety and efficacy. The order is effective as of March 26 and was applicable as of June 26. More

> Sorin ($SRN) has resumed manufacturing tissue heart valves. It had stopped during the second half of 2014 due to the implementation of a maintenance program in its Saluggia, Italy facility. Statement

> Sotera Wireless acquired Reflectance Medical for an undisclosed amount. The deal will bring in RMI's FDA-cleared Mobile CareGuide technology for the measurement of muscle oxygen saturation (SmO2) to determine the adequacy of tissue perfusion and muscle pH, an indication of acidosis. Release

> A joint panel of the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel recommended approval of the combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking from startup Avedro. Story

Biotech News

@FierceBiotech: Little Neos gets a $20M bankroll to prep ADHD drugs for FDA review. News | Follow @FierceBiotech

@JohnCFierce: Top 10 drug brands by payments to doctors, from the FiercePharma Marketing team. Special report | Follow @JohnCFierce

@DamianFierce: Hey so @FierceBiotech has a podcast now, and you can listen online. Listen | Follow @DamianFierce

> Can Neil Woodford reignite the U.K.'s taste for biotech investments? More

> Takeda's betting on its pipeline to spur a long-awaited turnaround. Item

> Hospira and Celltrion storm the EU with biosimilars of J&J's Remicade. Article

Pharma News

@FiercePharma: ICYMI yesterday: Serum Institute and Bharat Biotech race to get swine flu vaccines back on the market. FierceVaccines story | Follow @FiercePharma

@CarlyHFierce: In case you missed our newest special: Top 10 drug brands by payments to doctors. Report | Follow @CarlyHFierce

> J&J loses first court battle over Risperdal's breast-growth side effects. Story

> California lawmaker calling for more pricing transparency for costly meds. News

> Takeda will grow again in the coming year, COO Weber promises. Article

Drug Delivery News

> OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates. Report

> MIT team injects drug-carrying hydrogel that 're-heals' in the body. Story

> WHO adopts new safety needle policy, calling smart syringes an 'urgent priority.' Article

> Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel. Item

> FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug. News

Diagnostics News

> Israeli colon capsule maker reels in $24M in IPO and private placement. More

> Roche, BioMed X to jointly run diagnostics incubator in Germany. Article

> Foundation Medicine rides tailwinds of successful Q4 2014. Item

> Department of Defense gives contractor $14.8M to test so-called Sample-to-Sequence system. Report

> 23andMe scores FDA OK to market genetic carrier test direct to consumers. News

Pharma Marketing News

> Can Pfizer's new breast cancer med really cruise to $4B and beyond? Article

> Shire's Vyvanse brand team draws fire for aggressive binge-eating push. More

> British doctors lobby NHS to use cheap Avastin over Lucentis in AMD. Report

> With peglispro shunted aside, Lilly could go full-tilt after Lantus. Story

> Valeant to keep specialty Salix reps, but it's eyeing primary care for potential cuts. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.